A precision approach
The hypothalamic-pituitary axis is central to the endocrine system and many processes in the body. Kisspeptin and gonadotropin-releasing hormone, or GnRH, trigger downstream hormones like luteinizing hormone, or LH, estrogen, and testosterone. Our science is focused on developing new treatments that control these hormones by precisely targeting receptors in this axis.
Where do we go from here?
Our precision approach targets the hypothalamic-pituitary axis, which is implicated in a range of common diseases. By using this science, we aim to develop empowering medicines with a focus on areas of high unmet need.
Our lead investigational candidate, relugolix, and our second candidate, MVT-602, are currently in multiple Phase 2 and Ph3 trials across several indications.